Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 10/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4838661 | 1.00 | KMT2A (0.41) | KMT2AMAPTHTTBACE1NPC1 | |
| SCHEMBL4840066 | 0.92 | KMT2A (0.41) | KMT2AMAPTHTTNPC1RAB9A | |
| SCHEMBL4840076 | 0.92 | KMT2A (0.41) | KMT2AMAPTHTTNPC1RAB9A | |
| SCHEMBL4844365 | 0.88 | KMT2A (0.45) | KMT2AMAPTHTTBACE1NPC1 | |
| SCHEMBL4844376 | 0.88 | KMT2A (0.45) | KMT2AMAPTHTTBACE1NPC1 | |
| SCHEMBL4846278 | 0.87 | KMT2A (0.41) | KMT2AMAPTHTTRAB9AALDH1A1 | |
| SCHEMBL4846289 | 0.87 | KMT2A (0.41) | KMT2AMAPTHTTRAB9AALDH1A1 | |
| SCHEMBL4842745 | 0.85 | BACE1 (0.50) | KMT2AMAPTHTTBACE1RAB9A | |
| SCHEMBL4842684 | 0.85 | BACE1 (0.50) | KMT2AMAPTHTTBACE1RAB9A | |
| SCHEMBL4838257 | 0.85 | LMNA (0.42) | KMT2AMAPTHTTNPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1306373-B1 | 3,4-DIHYDROISOQUINOLINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2007-05-16 | — | — | EP | claimed |
| US-6956033-B2 | 3,4-dihydroisoquinoline derivative compound and a pharmaceutical agent comprising it as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-18 | — | — | US | claimed |
| US-20040077643-A1 | 3,4 Dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-22 | — | — | US | claimed |
| EP-1306373-A1 | 3,4-DIHYDROISOQUINOLINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-05-02 | — | — | EP | claimed |
| US-7378428-B2 | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-27 | — | — | US | disclosed |
| EP-1306373-B1 | 3,4-DIHYDROISOQUINOLINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2007-05-16 | — | — | EP | disclosed |
| EP-1306373-B1 | 3,4-DIHYDROISOQUINOLINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2007-05-16 | — | — | EP | disclosed |
| US-6956033-B2 | 3,4-dihydroisoquinoline derivative compound and a pharmaceutical agent comprising it as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-18 | — | — | US | disclosed |
| US-20050222138-A1 | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
| US-20040077643-A1 | 3,4 Dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1306373-A1 | 3,4-DIHYDROISOQUINOLINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077643-A1 | 3,4 Dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient | CNR1, CNR2, TRPV1 | KMT2A 921/4885MAPT 3538/4885HTT 3467/4885 |
| US-20050222138-A1 | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient | PARK7, MMP8, CDK7 | KMT2A 4642/4885MAPT 646/4885HTT 2525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.